{
    "nctId": "NCT01461044",
    "briefTitle": "An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer",
    "officialTitle": "An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin\u00ae (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 228,
    "primaryOutcomeMeasure": "Percentage of Participants Who Were Disease-Free for at Least 12 Months After Initial Diagnosis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients, \\>/=18 years of age\n* HER2-metastatic breast cancer or locally advanced breast cancer\n* Patients with Avastin as first line therapy administered for at least 12 months\n* Patients without disease progression after the beginning of Avastin treatment for at least 12 months\n\nExclusion Criteria:\n\n* Patients not willing to give informed consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}